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pentine and isoniazid. once weekly for 3 months, provides highly 
effective chenioprophylaxis. 
Other agents: Information about in i'itro and to a lesser extent irr 
tivo activities of two oxazolidinonc compounds (U-I 00592 and U- 
1 Oll7of)) and .I nitroimidaeole conipound (PA-8.24) suggest a possiblc. 
future role for one or more of these agents. 
In conclucion, development of effective new antimycobacterial 
agents has I~ggcd f.ir behind the need for thein. lnipruved public- 
priwte sector collaboration is needed to remedy the deficiency. 
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The use ofantibiotics has led to the emergence o f a  variety ofresistant 
bacteria which have cleai-ly added to the challenge of controlling 
infections with new agents. 
Misuse of antibiotics is responsible for a general pool of resistant 
\train< in the population where there is unrestricted sale of antibiotics, 
i.e. over the counter. 
Appropriate use of antibiotic policies to control drug resistance 
should be encouraged and implemented. In order to do so, an 
.intibiotic conunittee should be responsible for tlie formulation and 
supervision of nn antibiotic pohcy.The policy will improve patient 
care hy considrred iise of antibiotics for prophylaxis and therapy, 
make hettcr use of finance, retdrd the eiiiei-gence of multiplc 
antibiotic-re\irtait bacteria and improve education of junior doctor5 
by providing guidelines for appropriate therapy. 
The antibiotic committee will have to make rational choices 
among cquiv.ilent antibiotics and classes of drugs in order to sclcct 
the least expensive. most effective 3gents.Cost should determine tlie 
telec~ion when niicrobiological, pharniacologic and other relevant 
propertics are similar. 
Data on antibiotic susceptibility of bacterial isolates from the local 
area will assist the coninlittee in producing etfective guidance for the 
patient population.The 1abor.itory should give data on  the extent of 
resistance to a particular antibiotic. When n o  local microbiology 
I h m t o r y  exicts, the ~ntibiotic policy should be based upon a baric 
formulary; when resources for i i i i c rob io lo~~  are scarce, priority 
should be given to examination of samples from nosocominl lifc- 
threatening cases. 
Inappropri'ite use o f  antibiotic policies ha5 limited the choice of 
antibiotics, and there 19 a need for iiiore prudent use ofmtibiotics in 
the treatinent ofinfections, c\pecially ui developiiig countries. 
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There is now widejpread in vitru resistance to the coninion d r u g  
used for the management of pneumonia in developing countries. 
Data from both developed and developing countries, however, show 
that iiiore than 99% of pneuniococcl identified as penicillin resistant 
in the laboratory can be treated by adequate intravenous doses of 
penicillin or .urnpicillin. Trimethoprim-sulfaiiiethoxJzolr I \  leu active 
than mioxycillin for the nianagenient of scvcre pneumonia 
in  developing countries, The lesser activity of 
trimethoprini-sulfanietho~azole wac not directly related t o  level\  of 
antimicrobial resistance to that agent, suggectiq tli'it anioxvc.illin I \  
intrinsically more active against the coninion bacteri,il agent\ cau\ing 
pneumonia. Macrolide revstance has emerged as a major problem in  
Asia, with 8O'IB of pneuniococci isolated from children in China  
exhibiting re\istance to this class of agent. Guideline\ h r  the 
manageincnt of pneuinonia reiommLmd th'it tlie breakpoints for 
penicillin resistance should be increased, so that clinicians are not 
faced with dilemma of treating 'resistmt' strains with peiiicilhii. 
Nasopharyngeal screening programs give data on mtimicrubi.il 
resistance that are comparable to those obt'iined koni sterile-\itc 
speciniens. More data are required on the impact of penicillin 
resistance on the oral management of pnrunioni.~. (:iirrent dau  
would suggest that, where affordable, ordl amoxycillin \hould replaw 
crimethoprim-siilf~iiiethoxazole as the drug of choice fix the 
management of moderate to severe pncuniococc,~l piiciniioiiici i n  
developing countrics. 
Short course antibiotic therapy with 
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Due to favorable plidriiiacokinetics, shorter therapeutic regimens are 
now used with some of the newer macrolides. Thcte product\ ,ire 
characterized by rapid and substmtial intraccllul'ir accumulation, 
pxticul'irly in the lysosome~, followed by slow releaw from the cell\. 
so that intracellular concentrations can wrpacr blood c~ncen t r a t~ons  
by several hundred-fold. Among nixrohde\, azithromycin display\ 
the most important intracellular accumulatioii. making possible 
umplified docing. Most m.icrolide-~iisc.eptible respiratory t r x t  
infections can be etiiciently treated by once-a-day doring for 3 day\ 
with azithroinyrin; genital and eye infections causcd by W m y d i ~ i  
iruchonzatis are controlled with a single do\? of the drug. There I\ :I 
trend to extend the concept ufa cingle therapeutic dow in respir.itory 
infections. more p.irticularly in acute utitij media 'nid pharyiigitis, 
with the scinie ton1 dose as in the more conventional t r rmiet i t  (30 
m g i k g  for a child). Compared to the 3-day regimen, the single dosc 
assures the smie  serum hdf-life and AUC, but ni~xiii ium antibiotic 
concentrcitioiis appear earlier (at day 1 versus day 3)  Jnd reach higher 
levels. In theory, this could provide improved efficacy and  11mit the 
risk of resistance selection. The  single dose could l e d  t o  1 INPo 
conipliance if the drug I\ taken in presence of hexh  perwnnel. 
Improved compliance decreases the risk oftherapcutir failure md thc 
cost. Possible inconvenience includes more ride sffectc elwicxted 
with drug concentr&nis, particularly the gastruinte\tinal manifest- 
ations. 
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Azithroniycin (AZ) has proven in vitro bacteriologic xtivity a g ~ i ~ i s t  
many important comiiiunity-'isqiilreJ Gran-po\it~ve md <;ran- 
negative pathogens, J\ well J\ the xypical respiratory pclthogen\ I n  
